Table 1.

Patient and disease baseline characteristics.

Demographic or Patient Characteristic	IPI-926 Dose Cohort
	130 mg (N= 3)	160 mg (N=6)	Total (N=9)
Age, median (y)	53	60	57
Male	2	5	7
Female	1	1	2
White or Caucasian	3	5	8
Middle Eastern	0	1	1
ECOG PS
0	0	1	1
1	3	5	8
Smoker ≥10 pack-years	2	1	3
Location of primary
Tonsil	1	3	4
Oral Tongue	1	1	2
Base of Tongue	1	1	2
Unknown primary	0	1	1
HPV status
Positive	2	3	5
Negative	1	2	3
Unknown	0	1	1
No. of prior therapies for relapsed/metastatic cancer	1.6 (range: 1–3)	2.5 (range: 1–3)	2.2 (range: 1–3)
Prior cetuximab	2	5	7
Site(s) of measurable disease
Local-regional only	2	2	4
Distant only	1	2	3
Local-regional and Distant	0	2	2